ConductScience.org, home
Diseases
API referenceFor AI assistants

Disease · MONDO_0005657

aspergillosis

6 sourcesdiseases-2026-09-18-0.1.0

Download JSON
Cite this record

ConductScience Library. aspergillosis. Diseases, record MONDO_0005657. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0005657

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name
aspergillosis
Open Targets
Open Targets ID
MONDO_0005657
Open Targets
Other names
Infection due to Aspergillus
Open Targets
Disease Ontology
DOID:13564
Disease Ontology
MeSH
D001228
MeSH
NCI Thesaurus
C2886
NCI Thesaurus
Orphanet
ORPHA:1163
Orphanet
Highest stage of its drugs
Approval, for 8 of its 17 drugs, from DailyMed, EMA Human Drugs, PMDA and TTD
Open Targets

Drugs17

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

DrugChEMBL IDTypeOpen Targets' stageStage reported byReportsOf them trialsTrials shown hereSource
VORICONAZOLECHEMBL638Small moleculeApprovalDailyMed and EMA Human Drugs311010Drugs and targets
AMPHOTERICIN BCHEMBL267345Small moleculeApprovalDailyMed955Drugs and targets
POSACONAZOLECHEMBL1397Small moleculeApprovalDailyMed, EMA Human Drugs and TTD733Drugs and targets
CASPOFUNGINCHEMBL1630575Small moleculeApprovalEMA Human Drugs533Drugs and targets
ITRACONAZOLECHEMBL64391Small moleculeApprovalDailyMed533Drugs and targets
ISAVUCONAZOLECHEMBL409153Small moleculeApprovalEMA Human Drugs433Drugs and targets
ISAVUCONAZONIUM SULFATECHEMBL3137333Small moleculeApprovalDailyMed and PMDA311Drugs and targets
CASPOFUNGIN ACETATECHEMBL5314378Small moleculeApprovalDailyMed and PMDA200Drugs and targets
AMCIPATRICIN DIASCORBATECHEMBL1275839Small moleculePhase 3ClinicalTrials.gov111Drugs and targets
ANIDULAFUNGINCHEMBL264241Small moleculePhase 3ClinicalTrials.gov111Drugs and targets

1 to 10 of 17

See all 17 drugs

Targets5

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

TargetProteinIts drugs that act on itMechanismsHighest stage of those drugsGene in GenesSource
GUCY1A1Soluble guanylate cyclase1Soluble guanylate cyclase activatorPhase 2https://conductscience.org/library/genes/2982Drugs and targets
GUCY1A2Soluble guanylate cyclase1Soluble guanylate cyclase activatorPhase 2https://conductscience.org/library/genes/2977Drugs and targets
GUCY1B1Soluble guanylate cyclase1Soluble guanylate cyclase activatorPhase 2https://conductscience.org/library/genes/2983Drugs and targets
IFNGR1Interferon gamma receptor1Interferon gamma receptor agonistPhase 2https://conductscience.org/library/genes/3459Drugs and targets
IFNGR2Interferon gamma receptor1Interferon gamma receptor agonistPhase 2https://conductscience.org/library/genes/3460Drugs and targets

Trials29

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs.

TrialTitlePhaseParticipantsResults first postedConditionsDrugsLinked bySource
NCT00634049Isavuconazole in the Treatment of Renally Impaired Aspergillosis and Rare FungiPhase 31492016-01-11Aspergillosis, Invasive Fungal InfectionsISAVUCONAZOLEIts record names the diseaseClinicalTrials.gov
NCT02180165Assessing the Safety and Efficacy of MK-5592 (Posaconazole) in Japanese Participants With Fungal Infection (MK-5592-101)Phase 31162019-01-11AspergillosisPOSACONAZOLEIts record names the diseaseClinicalTrials.gov
NCT00404092Caspofungin Maximum Tolerated Dose in Patients With Invasive AspergillosisPhase 2462013-01-21Invasive AspergillosisCASPOFUNGINOpen Targets' reading, confirmed by NLM's indexing of its papersClinicalTrials.gov
NCT00836875A Study To Evaluate The Safety Of Voriconazole As Treatment Of Invasive Aspergillosis (Fungal Infection) And Other Rare Molds In ChildrenPhase 3312014-06-23Invasive AspergillosisVORICONAZOLEOpen Targets' reading, confirmed by NLM's indexing of its papersClinicalTrials.gov
NCT03816176A Study to Evaluate Isavuconazonium Sulfate for the Treatment of Invasive Aspergillosis (IA) or Invasive Mucormycosis (IM) in Pediatric ParticipantsPhase 2312023-09-21Invasive Mucormycosis, Invasive AspergillosisISAVUCONAZONIUM SULFATEOpen Targets' reading, confirmed by NLM's indexing of its papersClinicalTrials.gov
NCT04218851Posaconazole (MK-5592) Intravenous and Oral in Children With Invasive Aspergillosis (IA) (MK-5592-104)Phase 2312025-01-14Invasive AspergillosisPOSACONAZOLEOpen Targets' reading, confirmed by NLM's indexing of its papersClinicalTrials.gov
NCT03672292Evaluate Safety and Efficacy of the Coadministration of Ibrexafungerp With Voriconazole in Patients With Invasive Pulmonary AspergillosisPhase 2222024-08-09Invasive Pulmonary AspergillosisIBREXAFUNGERP, VORICONAZOLEOpen Targets' reading of its recordClinicalTrials.gov
NCT00158730Study Safety/Efficacy of AmBisome Loading Dose Regimen Versus Standard AmBisome Regimen for Initial TreatmentPhase 3800Invasive Aspergillosis, Other Fungal InfectionsAMPHOTERICIN BOpen Targets' reading of its recordClinicalTrials.gov
NCT05101187Olorofim Aspergillus Infection StudyPhase 3225Invasive AspergillosisOLOROFIMOpen Targets' reading, confirmed by NLM's indexing of its papersClinicalTrials.gov
NCT03656081Chronic Pulmonary Aspergillosis and Ambisome Aerosol with ItraconazolePhase 3224Chronic Pulmonary AspergillosisAMPHOTERICIN B, ITRACONAZOLEOpen Targets' reading of its recordClinicalTrials.gov

1 to 10 of 29

See all 29 trials

Comparisons in its trials7

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

ComparisonGroup 1, with the outcomeGroup 2, with the outcomeParticipantsTrialSource
Renally Impaired (RI) vs Not Renally Impaired (NRI): serious adverse events43 of 5946 of 87146NCT00634049Trial comparisons
Voriconazole: 2 to <12 Years vs Voriconazole: 12 to <18 Years: Attributable Mortality - Number of Participant Deaths0 of 110 of 2031NCT00836875Trial comparisons
Voriconazole: 2 to <12 Years vs Voriconazole: 12 to <18 Years: serious adverse events6 of 119 of 2031NCT00836875Trial comparisons
Age Cohort 1 (2 -< 12 Years Old) vs Age Cohort 2 (12 -< 18 Years Old): deaths from any cause2 of 144 of 1731NCT04218851Trial comparisons
Age Cohort 1 (2 -< 12 Years Old) vs Age Cohort 2 (12 -< 18 Years Old): serious adverse events4 of 148 of 1731NCT04218851Trial comparisons
SCY-078 Plus Voriconazole vs Voriconazole Mono-therapy: deaths from any cause3 of 101 of 1222NCT03672292Trial comparisons
SCY-078 Plus Voriconazole vs Voriconazole Mono-therapy: serious adverse events6 of 105 of 1222NCT03672292Trial comparisons

Papers from its trials17

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMIDListed asTrials listing itSource
23335740RESULT1PubMed
21911573RESULT1PubMed
42553256DERIVED1PubMed
42446237DERIVED1PubMed
41589852DERIVED1PubMed
41175884DERIVED1PubMed
39540734DERIVED1PubMed
39378343DERIVED1PubMed
37185921DERIVED1PubMed
35429465DERIVED1PubMed

1 to 10 of 17

See all 17 papers from its trials

Data dates

The date of each source this release read.

Open Targets
2026-09-18
Open Targets
Drug links and their checks, from Drugs and targets
2026-09-18
Drugs and targets
ClinicalTrials.gov, from Trials
2026-11-12
Trials
Comparisons, from Trial comparisons
2026-03-23
Trial comparisons
PubMed, for the checks
2026-11-06
PubMed
MeSH, for the checks
2026-11-10
MeSH

Sources 6

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • NLM's MeSHNLM's terms
  • Open TargetsCC0 1.0
  • PubMedNLM's terms
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • NLM's MeSHNLM's
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/MONDO_0005657

GET https://conductscience.org/api/diseases/v1/MONDO_0005657/trials?page=2

API referenceFor AI assistants